**Aim:** Betatrophin, a recently identified circulating adipokine, affects lipid and glucose metabolism. However, association between plasma betatrophin levels and atherosclerotic diseases, such as coronary artery disease (CAD) and peripheral artery disease (PAD), has not been elucidated.

**Methods:** We investigated plasma betatrophin levels in 457 patients undergoing elective coronary angiography who also had ankle-brachial index (ABI) test for PAD screening.

**Results:** Of the 457 study patients, CAD was present in 241 patients (53%) (1-vessel [1-VD], \( n = 99 \); 2-vessel [2-VD], \( n = 71 \); 3-vessel disease [3-VD], \( n = 71 \)). Compared to 216 patients without CAD, 241 with CAD had higher betatrophin levels (median 1120 vs. 909 pg/mL, \( p < 0.001 \)). A stepwise increase in betatrophin levels was found depending on the number of >50% stenotic coronary vessels: 909 in CAD(-), 962 in 1-VD, 1097 in 2-VD, and 1393 pg/ml in 3-VD (\( p < 0.001 \)). Betatrophin levels correlated with the number of >25% stenotic segments (\( r = 0.24, p < 0.001 \)). PAD (ABI < 0.9) was found in 41 patients (9%). Plasma betatrophin levels were also significantly higher in 41 patients with PAD than in 416 without PAD (1354 vs. 981 pg/mL, \( p < 0.001 \)). In the multivariate analysis, betatrophin levels were not a factor for CAD, but they were a significant factor for 3-VD and PAD independent of atherosclerotic risk factors. The odds ratios for 3-VD and PAD were 1.06 (95%CI 1.01-1.11) and 1.07 (95%CI 1.01-1.13) for a 100-pg/mL increase in betatrophin levels, respectively (\( p < 0.05 \)).

**Conclusion:** Plasma betatrophin levels were associated with the presence and severity of CAD and PAD, suggesting betatrophin has a role in atherosclerosis.

**Key words:** Betatrophin, Coronary artery disease, Peripheral artery disease

**Introduction**

Betatrophin, also called angiopoietin-like protein 8 (ANGPTL8), is a recently identified circulating adipokine, mainly produced in the liver and adipose tissues, which affects both glucose and lipid metabolism \(^1\). In animal models, betatrophin promoted pancreatic beta cell proliferation\(^2\) and regeneration\(^3\), thereby improving glucose tolerance. However, another study indicated betatrophin affected neither beta cell expansion nor glucose metabolism\(^6\). Most studies showed that betatrophin levels in diabetic patients are higher than in non-diabetic patients\(^5,8\), but some studies reported decreased levels in diabetic patients\(^9\) or no difference between diabetic and non-diabetic patients\(^10,11\). In lipid metabolism, betatrophin inhibited lipoprotein lipase (LPL) activity, thereby causing increased triglyceride (TG) levels\(^12,13\). Although some studies reported blood betatrophin levels positively correlated with TG levels\(^7,14\), others...
showed no correlation between betatrophin and TG levels. Thus, the associations between blood betatrophin levels and impaired glucose metabolism or atherogenic lipid profiles remain controversial.

Recently, Huang et al.15 reported serum betatrophin levels were high in 22 diabetic patients with coronary artery disease (CAD) or stroke. Maurer et al.14 also showed that serum betatrophin levels correlated with carotid arterial wall thickness (r=0.26) in 535 subjects, of whom 32 (6%) had DM. However, blood betatrophin levels in patients with atherosclerotic diseases, such as CAD and peripheral artery disease (PAD), have not been clarified yet. To elucidate whether or not plasma betatrophin levels are associated with the presence and severity of CAD and PAD, independent of glucose and lipid metabolism, our cross-sectional study was performed in 457 patients undergoing elective coronary angiography who also underwent an ankle-brachial index (ABI) test to screen for PAD16.

**Methods**

**Study Patients**

We investigated plasma betatrophin levels in 457 consecutive patients undergoing elective coronary angiography for suspected CAD at Tokyo Medical Center who also had an ABI test to screen for PAD from July 2008 to September 2016. The ABI on each leg was measured in a supine position after five mins of rest using VaSera VS-1000 instrument (Fukuda Denshi, Tokyo, Japan). The lower of the two ABIs was used for further analysis, and PAD was defined as an ABI of <0.916. Patients with a history of percutaneous coronary intervention or cardiac surgery were excluded from this study. Any patients with acute coronary syndrome, such as acute myocardial infarction and unstable angina, were also excluded. Hypertension was defined as blood pressure of ≥140/90 mmHg or on drugs, and 272 (60%) patients were taking anti-hypertensive drugs. Hypercholesterolemia was defined as an LDL-cholesterol (LDL-C) level of >140 mg/dL or on drugs, and 159 (35%) patients were taking LDL-C lowering drugs, such as a statin or ezetimibe. Hypertriglyceridemia was defined as a TG level of >150 mg/dL or on drugs, and 33 (7%) were taking TG lowering drugs, such as fibrates, nicotinates, or EPA. DM (a fasting plasma glucose [FPG] level of ≥126 mg/dL or on treatment) was present in 117 (26%) patients, and 171 (37%) were smokers (≥10 pack-years). Our study was approved by the institutional ethics committee of our hospital (R07-054/R15-056). After written informed consent was obtained, overnight-fasting blood samples were taken on the morning of the day when coronary angiography was performed.

**Measurement of Plasma Betatrophin and C-reactive Protein Levels**

Blood samples were collected in EDTA-containing tubes. Plasma was stored at −80°C. Plasma betatrophin levels were measured by an enzyme-linked immunosorbent assay using a commercially available kit (WUHAN EIAab Science; Catalog number E11644h, China) at Ochanomizu University according to the manufacturer’s instructions. The intra-assay and inter-assay coefficients of variation were <8% and <10%, respectively. Plasma high-sensitivity C-reactive protein (hsCRP) levels were also measured by a BNII nephelometer (Dade Behring, Tokyo, Japan).

**Coronary Angiography**

Angiograms were recorded on a cineangiogram system (Philips Electronics Japan, Tokyo, Japan). CAD was defined as at least one coronary artery having ≥50% luminal diameter stenosis on angiograms. The CAD severity was represented as the number of >50% stenotic vessels and the number of >50% and >25% stenotic segments. Coronary artery segments were defined as 29 segments according to the Coronary Artery Surgery Study classification. All angiograms were evaluated by a single cardiologist (Y.M.), blinded to the clinical and laboratory data.

**Statistical Analysis**

Any differences between two groups were evaluated by an unpaired t-test for parametric variables, by Mann-Whitney U test for nonparametric variables, and by chi-squared test for categorical variables. Any differences among ≥3 groups were evaluated by an analysis of variance with Scheffe’s test for parametric variables, by Kruskal-Wallis test with Steel-Dwass test for nonparametric variables, and by chi-squared test for categorical variables. The correlations between plasma betatrophin levels and lipid and glucose parameters as well as the severity of CAD or PAD were evaluated by Spearman’s rank correlation test and multiple linear regression analysis. A multiple logistic regression analysis was used to determine the independent associations between betatrophin levels and the presence of CAD or PAD. In model 1, only 7 and 4 variables were entered in the analysis of CAD or 3-VD and of PAD, because the numbers of patients with 3-VD and PAD were 71 and 41, respectively.17 In addition to betatrophin levels, we selected these variables because they are associated with CAD or PAD among atherosclerotic risk factors. However, all
### Results

Among the 457 study patients, CAD was present in 241 patients (53%) (1-vessel disease [1-VD], \( n = 99 \); 2-vessel disease [2-VD], \( n = 71 \); 3-vessel disease [3-VD], \( n = 71 \)). Compared to 216 patients without CAD, 241 patients with CAD were older, generally male, and had a higher prevalence of hypertension, hypercholesterolemia, hypertriglyceridemia, DM, and smoking (Table 1). CAD patients also had lower HDL-cholesterol and higher TG and hsCRP levels and were more often taking LDL-C lowering drugs, but not TG lowering drugs, than those without CAD. Notably, plasma betatrophin levels were significantly higher in patients with CAD than in those without CAD. The results are presented as the mean ± SD or median and interquartile range.

#### Table 1. Clinical characteristics and plasma betatrophin levels of patients with and without CAD

|                | CAD(-) \( n = 216 \) | \( P \)-value | CAD \( n = 241 \) | 1-VD \( n = 99 \) | 2-VD \( n = 71 \) | 3-VD \( n = 71 \) | \( P \)-value Among 4 groups |
|----------------|---------------------|--------------|-------------------|-----------------|-----------------|-----------------|-----------------------------|
| Age (years)    | 66 ± 12             | < 0.001      | 70 ± 10           | 68 ± 10         | 69 ± 10         | 72 ± 7          | < 0.001                    |
| Gender (male)  | 137 (63%)           | 0.003        | 184 (76%)         | 76 (77%)        | 50 (70%)        | 58 (82%)        | 0.010                      |
| BMI (kg/m²)    | 24.6 ± 12.3         | 0.282        | 23.7 ± 3.6        | 24.0 ± 4.0      | 23.8 ± 3.2      | 23.1 ± 3.2      | 0.655                      |
| Hypertension   | 133 (62%)           | < 0.001      | 191 (79%)         | 77 (78%)        | 55 (77%)        | 59 (83%)        | < 0.001                    |
| SBP (mmHg)     | 130 ± 20            | 0.285        | 133 ± 21          | 131 ± 20        | 138 ± 21        | 129 ± 24        | 0.049                      |
| Diabetes mellitus | 30 (14%) | < 0.001      | 87 (36%)          | 30 (30%)        | 27 (38%)        | 30 (42%)        | < 0.001                    |
| FPG (mg/dL)    | 100 ± 25            | 0.003        | 108 ± 31          | 104 ± 24        | 109 ± 32        | 111 ± 37        | 0.010                      |
| HBA1c (%)      | 5.9 ± 0.6           | < 0.001      | 6.3 ± 1.0         | 6.2 ± 0.9       | 6.4 ± 1.0       | 6.5 ± 1.1       | < 0.001                    |
| Smoking        | 66 (31%)            | 0.005        | 105 (44%)         | 45 (45%)        | 30 (42%)        | 30 (42%)        | 0.037                      |
| Hypercholesterolemia | 81 (38%) | < 0.001      | 135 (56%)         | 51 (52%)        | 43 (61%)        | 41 (58%)        | 0.001                      |
| LDL-C (mg/dL)  | 111 ± 29            | 0.354        | 114 ± 32          | 112 ± 34        | 116 ± 32        | 115 ± 29        | 0.629                      |
| Medication(+)  | 53 (28%)            | < 0.001      | 106 (44%)         | 41 (41%)        | 32 (45%)        | 33 (46%)        | < 0.001                    |
| Statin         | 52 (24%)            | < 0.001      | 105 (44%)         | 40 (40%)        | 32 (45%)        | 33 (46%)        | < 0.001                    |
| Ezetimibe      | 1 (0%)              | 0.628        | 2 (1%)            | 1 (1%)          | 1 (1%)          | 0 (0%)          | 0.706                      |
| Hypertriglyceridemia | 63 (29%) | 0.034        | 93 (39%)          | 35 (35%)        | 31 (44%)        | 27 (38%)        | 0.123                      |
| TG (mg/dL)     | 122 ± 64            | 0.013        | 137 ± 67          | 136 ± 65        | 147 ± 76        | 128 ± 60        | 0.028                      |
| Medication(+)  | 11 (5%)             | 0.096        | 22 (8%)           | 8 (8%)          | 7 (7%)          | 7 (7%)          | 0.385                      |
| Fibrates       | 1 (0%)              | 0.063        | 8 (3%)            | 3 (3%)          | 3 (4%)          | 2 (3%)          | 0.154                      |
| Nicotinates    | 6 (3%)              | 0.415        | 4 (2%)            | 3 (3%)          | 0 (0%)          | 1 (1%)          | 0.481                      |
| EPA            | 4 (2%)              | 0.155        | 10 (4%)           | 2 (2%)          | 4 (6%)          | 4 (6%)          | 0.204                      |
| HDL-C (mg/dL)  | 58 ± 15             | < 0.001      | 51 ± 13           | 54 ± 14         | 50 ± 11         | 49 ± 12         | < 0.001                    |
| hsCRP (mg/L)   | 0.49 [0.25, 1.27]   | 0.004        | 0.69 [0.35, 1.61] | 0.62 [0.30, 1.33] | 0.64 [0.40, 1.42] | 0.88 [0.42, 2.00] | 0.008                      |
| Betatrophin levels (pg/mL) | 909 [645, 1333] | < 0.001      | 1120 [761, 1517]  | 962 [641, 1384]  | 1097 [830, 1421]  | 1393 [957, 1621]  | < 0.001                    |
| PAD (ABI < 0.9) | 6 (3%)              | < 0.001      | 35 (15%)          | 9 (9%)          | 7 (10%)         | 19 (27%)        | < 0.001                    |

Data represent the mean ± SD or the number (%) of patients, with the exception of hsCRP and betatrophin levels which are presented as the median value and interquartile range.

BMI = body mass index; SBP = systolic blood pressure; FPG = fasting plasma glucose; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; TG = triglyceride.

Atherosclerotic risk factors such as betatrophin levels were entered into model 2. In model 2 for PAD, CAD was also entered to see the association between betatrophin levels and PAD independent of CAD. A \( p \)-value of < 0.05 was considered to be statistically significant. The results are presented as the mean ± SD or median value.
notic vessels (β=0.02, p<0.05) but did not with the numbers of >50% and >25% stenotic segments.

Among the 457 study patients, PAD (ABI<0.9) was found in 41 (9%) patients (6 of 216 [3%] patients without CAD and 35 of 241 [15%] with CAD). Compared to 416 patients without PAD, 41 patients with PAD were older and had higher prevalence of hypertension, hypercholesterolemia, and smoking (Table 2). Patients with PAD also had lower HDL-cholesterol and higher hsCRP levels and were more often taking LDL-C lowering drugs but not TG lowering drugs than those without PAD. Notably, patients with PAD had a higher prevalence of CAD (85% vs. 50%), especially 3-VD (46% vs. 13%), than those without PAD (p<0.001). Plasma betatrophin levels were significantly higher in patients with PAD than in those without PAD (median 1354 vs. 981 pg/mL, p<0.001) (Fig. 2). Betatrophin levels also significantly correlated with ABI (rs=−0.17, p<0.001 by Spearman's rank correlation test). In multiple linear regression analysis including age, BMI, SBP, HbA1c, LDL-C, TG, and HDL-C levels, betatrophin levels significantly correlated with ABI (β=−0.01, p<0.001).

DM was present in 117 (26%) of 457 study patients. Compared to 340 patients without DM, 117 with DM more often had CAD (74% vs. 45%), especially 3-VD (26% vs. 12%) (p<0.001). Betatrophin levels were significantly higher in patients with DM than in those without DM (median 1305 vs. 1045 pg/mL, p<0.001). Betatrophin levels significantly correlated with age (rs=0.42) and HbA1c (rs=0.18) and hsCRP (rs=0.22) levels (p<0.001), but they did not correlate with BMI and FPG or TG levels. Even after excluding 159 patients with LDL-C lowering drugs and 33 patients with TG lowering drugs, betatrophin levels correlated with age (rs=0.42), HbA1c (rs=0.19) and hsCRP (rs=0.21) (p<0.001), but not with BMI and FPG or TG levels.

Table 3 shows the odds ratios of atherosclerotic risk factors and betatrophin levels for CAD and 3-VD in univariate and multivariate analysis. To elucidate the independent associations between betatrophin levels and CAD or 3-VD, variables (age, gender, BMI, hypertension, smoking, DM, LDL-C lowering and TG lowering drugs, and LDL-C, HDL-C, TG, and betatrophin levels) were entered into a multiple logistic regression model. In both models 1 and 2, plasma betatrophin levels were not a significant factor for CAD but were a significant factor for 3-VD independent of atherosclerotic risk factors. The odds ratio for

Fig. 1. Associations between plasma betatrophin levels and the presence of CAD or the number of stenotic coronary vessels

The plasma betatrophin levels were significantly higher in CAD than in CAD(-) (left). Furthermore, betatrophin levels in four groups of CAD(-), 1-VD, 2-VD, and 3-VD were 909, 962, 1097, and 1393 pg/mL, respectively, and were highest in 3-VD (p<0.001 by Kruskal-Wallis test) (right). Betatrophin levels in 3-VD were significantly higher than those in CAD(-) and 1-VD (p<0.05). The central line represents the median, and the box represents the 25th to 75th percentiles. The whiskers represent the lowest and highest value in the 25th percentile minus 1.5 IQR and 75th percentile plus 1.5 IQR, respectively.
Table 2. Clinical characteristics and plasma betatrophin levels of patients with and without PAD

|                      | PAD(-) (n=416) | PAD (+) (n=41) | P value |
|----------------------|----------------|---------------|---------|
| Age (years)          | 67 ± 11        | 73 ± 9        | 0.001   |
| Gender (male)        | 290 (70%)      | 31 (76%)      | 0.431   |
| BMI (kg/m²)          | 24.2 ± 9.2     | 23.4 ± 3.6    | 0.576   |
| Hypertension         | 286 (69%)      | 38 (93%)      | 0.001   |
| Systolic blood pressure (mmHg) | 131 ± 20    | 133 ± 30      | 0.755   |
| Diabetes mellitus    | 102 (25%)      | 15 (37%)      | 0.091   |
| FPG (mg/dL)          | 104 ± 28       | 105 ± 32      | 0.737   |
| HBA1c (%)            | 6.1 ± 0.8      | 6.4 ± 1.0     | 0.115   |
| Smoking              | 148 (36%)      | 23 (56%)      | 0.010   |
| Hypercholesterolemia | 188 (45%)      | 28 (68%)      | 0.005   |
| LDL-cholesterol (mg/dL) | 112 ± 30    | 115 ± 31      | 0.542   |
| Medication (+)       | 138 (33%)      | 21 (51%)      | 0.021   |
| Statin               | 136 (33%)      | 21 (51%)      | 0.017   |
| Ezetimibe            | 3 (1%)         | 0 (0%)        | 0.585   |
| Hypertriglyceridemia | 136 (33%)      | 20 (49%)      | 0.057   |
| TG (mg/dL)           | 129 ± 67       | 137 ± 63      | 0.458   |
| Medication (+)       | 29 (7%)        | 4 (10%)       | 0.733   |
| Fibrates             | 8 (2%)         | 1 (2%)        | 0.821   |
| Nicotinates          | 9 (2%)         | 1 (2%)        | 0.908   |
| EPA                  | 12 (3%)        | 2 (5%)        | 0.480   |
| HDL-cholesterol (mg/dL) | 55 ± 14    | 48 ± 10       | 0.004   |
| hsCRP (mg/L)         | 0.56 [0.28, 1.32] | 1.29 [0.45, 2.82] | 0.002 |
| Betatrophin levels (ng/mL) | 981 [670, 1402] | 1354 [1072, 1783] | <0.001 |
| CAD                  | 206 (50%)      | 35 (85%)      | <0.001  |
| 1-VD                 | 90 (22%)       | 9 (22%)       | 0.975   |
| 2-VD                 | 64 (15%)       | 7 (17%)       | 0.950   |
| 3-VD                 | 52 (13%)       | 19 (46%)      | <0.001  |

Data represent the mean ± SD or the number (%) of patients, with the exception of hsCRP and betatrophin levels which is presented as the median value and interquartile range.

Fig. 2. Association between plasma betatrophin levels and the presence of PAD

The plasma betatrophin levels were significantly higher in PAD than in PAD(-). The central line represents the median, and the box represents the 25th to 75th percentiles. The whiskers represent the lowest and highest value in the 25th percentile minus 1.5 interquartile range (IQR) and 75th percentile plus 1.5 IQR, respectively.
3-VD was 1.06 (95%CI = 1.01-1.11) for a 100-<i>pg/mL</i> increase in betatrophin levels (<i>p</i> < 0.025). <i>Table 3</i>.<br><br><i>Table 4</i> shows the odds ratios of atherosclerotic risk factors and betatrophin levels for PAD in univariate and multivariate analyses. To elucidate the independent association between betatrophin levels and PAD, variables (age, gender, BMI, hypertension, smoking, DM, LDL-C lowering and TG lowering drugs, LDL-C, HDL-C, TG and betatrophin levels, and CAD) were entered into a multiple logistic regression model. In both models 1 and 2, betatrophin levels were a significant factor for PAD independent of atherosclerotic risk factors. The odds ratio for PAD was 1.07 (95%CI = 1.01-1.13) for a 100-<i>pg/mL</i> increase in betatrophin levels (<i>p</i> < 0.05).<i>Table 4</i>.<br><br>**Discussion**<br><br>In the present study, plasma betatrophin levels were significantly higher in patients with CAD, especially in 3-VD, than in those without CAD, and they correlated with CAD severity, defined as the numbers of stenotic vessels and segments. Moreover, betatrophin levels were also higher in patients with PAD than in those without PAD, and they correlated with PAD severity, defined as ABI. Although betatrophin levels correlated with HbA1c, but not with TG levels, betatrophin levels were found to be a significant factor for 3-VD as well as PAD independent of atherosclerotic risk factors.<br><br>Betatrophin was suggested to inhibit LPL activity and increase TG levels<sup>12, 13</sup>). However, the association between blood betatrophin levels and TG levels remains controversial, with some studies indicating positive correlation<sup>7, 14</sup>) and others indicating no correlation<sup>5, 6, 11</sup>). In our study, 159 (35%) and 33 (7%) of the 457 study patients were taking LDL-C lowering drugs (statin or ezetimibe) and TG lowering drugs (fibrates, nicotinates or EPA), respectively. However, we also found no correlation between plasma betatroph-
plasma ANGPTL3 were associated with a lower risk of MI and lower TG levels. Furthermore, plasma ANGPTL3 levels were correlated with carotid arterial wall thickness. Therefore, ANGPTL3 may have a promotive effect on atherosclerosis progression.

Betatrophin (ANGPTL8) and ANGPTL3 are suggested to be most closely related among the ANGPTL family because of their similar gene structure. Betatrophin and ANGPTL3 co-operate in the regulation of TG levels. Moreover, betatrophin was reported to promote ANGPTL3’s ability to bind and then inhibit LPL. These findings suggest that betatrophin, as well as ANGPTL3, may have atherogenic effect. One study reported that serum betatrophin levels were higher in 22 diabetic patients with CAD or stroke than in 101 diabetic patients without such disease. Another study reported that serum betatrophin levels correlated positively with carotid arterial wall thickness. Our study showed that plasma betatrophin levels were significantly higher in patients with CAD, especially 3-VD, and PAD independent of lipid levels and DM.

The ANGPTL protein family contains seven typical members, which are characterized by a coiled-coil domain at N-terminus, a fibrinogen-like domain at C-terminus, and a signal peptide for protein secretion. Betatrophin (ANGPTL8) is an atypical member of ANGPTL because it lacks a fibrinogen-like domain but shares common ancestors with ANGPTL3 and ANGPTL4. Both ANGPTL3 and ANGPTL4 are shown to inhibit LPL in vitro, suggesting a role in lipid metabolism. In animal models, ANGPTL4 overexpression reduced atherosclerosis with no change in lipid levels. However, Smart-Halajko et al. reported no association between plasma ANGPTL4 levels and CAD risk or TG levels in 666 subjects. Despite similar biochemical effects in vitro, reduced ANGPTL3 expression reduced atherosclerosis and TG levels. In humans, lower levels of plasma ANGPTL3 were associated with a lower risk of MI and lower TG levels. Furthermore, plasma ANGPTL3 levels were correlated with carotid arterial wall thickness. Therefore, ANGPTL3 may have a promotive effect on atherosclerosis progression.

Betatrophin (ANGPTL8) and ANGPTL3 are suggested to be most closely related among the ANGPTL family because of their similar gene structure. Betatrophin and ANGPTL3 co-operate in the regulation of TG levels. Moreover, betatrophin was reported to promote ANGPTL3’s ability to bind and then inhibit LPL. These findings suggest that betatrophin, as well as ANGPTL3, may have atherogenic effect. One study reported that serum betatrophin levels were higher in 22 diabetic patients with CAD or stroke than in 101 diabetic patients without such disease. Another study reported that serum betatrophin levels correlated positively with carotid arterial wall thickness. Our study showed that plasma betatrophin levels were significantly higher in patients with CAD, especially 3-VD, and PAD independent of lipid levels and DM.

The ANGPTL protein family contains seven typical members, which are characterized by a coiled-coil domain at N-terminus, a fibrinogen-like domain at C-terminus, and a signal peptide for protein secretion. Betatrophin (ANGPTL8) is an atypical member of ANGPTL because it lacks a fibrinogen-like domain but shares common ancestors with ANGPTL3 and ANGPTL4. Both ANGPTL3 and ANGPTL4 are shown to inhibit LPL in vitro, suggesting a role in lipid metabolism. In animal models, ANGPTL4 overexpression reduced atherosclerosis with no change in lipid levels. However, Smart-Halajko et al. reported no association between plasma ANGPTL4 levels and CAD risk or TG levels in 666 subjects. Despite similar biochemical effects in vitro, reduced ANGPTL3 expression reduced atherosclerosis and TG levels. In humans, lower levels of plasma ANGPTL3 were associated with a lower risk of MI and lower TG levels. Furthermore, plasma ANGPTL3 levels were correlated with carotid arterial wall thickness. Therefore, ANGPTL3 may have a promotive effect on atherosclerosis progression.

Table 4. Factors associated with PAD (Univariate and multivariate regression analysis of 457 study patients)

| Factor                        | Univariate          | Multivariate         |
|-------------------------------|---------------------|----------------------|
|                               | Odds ratio (95%CI)  | P value              |
|                               |                     |                      |
| PAD                           | Odds ratio (95%CI)  | P value              |
|                               |                     |                      |
| Age (per 10 yrs increase)     | 1.96 (1.33-2.91)    | 0.001                |
| Male gender                   | 1.35 (0.64-2.83)    | 0.432                |
| BMI (per 1 kg/m² increase)    | 0.97 (0.90-1.06)    | 0.527                |
| Hypertension                  | 5.76 (1.75-18.9)    | 0.004                |
| Diabetes mellitus             | 1.78 (0.91-3.48)    | 0.095                |
| Smoking                       | 2.31 (1.21-4.43)    | 0.011                |
| LDL-C (per 10 mg/dL increase) | 1.03 (0.93-1.14)    | 0.577                |
| LDL-C lowering drug           | 2.12 (1.11-4.03)    | 0.023                |
| TG (per 10 mg/dL increase)    | 1.02 (0.97-1.07)    | 0.428                |
| TG lowering drug              | 1.44 (0.48-4.33)    | 0.513                |
| HDL-C (per 10 mg/dL increase) | 0.69 (0.53-0.90)    | 0.007                |
| Betatrophin (per 100 mg/dL increase) | 1.11 (1.05-1.16) | <0.001               |
| CAD                           | 5.95 (2.45-14.4)    | <0.001               |
241 with CAD (15%). The PAD prevalence was similar to that reported by Lee et al. (5 of 119 without CAD [4%] and 385 of 2424 with CAD [16%] among 2,543 patients undergoing coronary angiography). No previous studies have investigated blood betatrophin levels in patients with PAD. We reported high levels of plasma betatrophin in patients with PAD. Betatrophin levels correlated with PAD severity, defined as ABI, and were a significant factor for PAD independent of atherosclerotic risk factors, suggesting a role of betatrophin in atherosclerosis progression. However, the mechanism of how betatrophin affects atherosclerosis and the direct atherogenic effect of betatrophin has not been clarified. Further studies are needed to elucidate the mechanism of the atherogenic effect of betatrophin and determine whether or not betatrophin has a direct atherogenic effect in addition to its effects on glucose and lipid metabolism.

Study Limitations

Our study has several limitations. First, we used the betatrophin kit manufactured by EIAab Science, which recognizes the N-terminus of betatrophin. However, some studies used the kit by Phoenix, which recognizes the C-terminus. The N-terminal kit measures the full-length protein, while the C-terminal kit measures total betatrophin species, including the full-length protein and C-terminal fragments. Using different kits may have caused different results. However, increased levels were reported in spite of the use of different kits, and the N-terminal kit is more commonly used than the C-terminal kit. Moreover, we did not measure LPL activity and insulin levels. One of the study limitations is lack of data on the role of betatrophin in atherosclerosis. Second, coronary angiography was used to evaluate coronary atherosclerosis. Angiography cannot visualize plaques and only shows lumen characteristics. However, IVUS, which can visualize coronary plaques, was not always performed in our patients. Third, PAD was found in 6 of 216 patients without CAD (3%) and 35 of 241 with CAD (15%). This prevalence of PAD was similar to that reported by Lee et al. However, the small number of patients with PAD was one of major limitations. Moreover, in our study, an ABI test was used to screen for PAD, and PAD was defined as ABI of <0.9. Angiography or computed tomography were not always performed to confirm the PAD diagnosis. This is one of study limitations. Fourth, our study was cross-sectional in nature and could not establish causality since it only showed some associations and proposed some hypotheses. Finally, our study was performed on Japanese patients undergoing coronary angiography, who are generally considered to be a highly select population at high risk for CAD. Our results, therefore, may not be applicable to the general or other ethnic populations.

Conclusion

Plasma betatrophin levels were high in CAD patients, especially in 3-VD, and they correlated with the severity of CAD. Furthermore, betatrophin levels were also high in patients with PAD. Although betatrophin levels correlated with HbA1c but not TG levels, betatrophin levels were found to be a significant factor associated with 3-VD and PAD independent of atherosclerotic risk factors. Our findings, thus, suggest that betatrophin may promote atherosclerotic disease development, such as CAD and PAD.

Funding

This study was supported in part by a grant from Honjo International Scholarship Foundation. Financial funding was also provided by Bayer Yakuhin Ltd. and Pfizer Japan Inc.; however, these sponsors had no role in the design, analysis or interpretation of our study.

Conflict of interest

Our study has no conflict of interest to disclose.

References

1) Zhang R, Abou-Samra AB. A dual role of lipasin (betatrophin) in lipid metabolism and glucose homeostasis: consensus and controversy. Cardiovasc Diabetol, 2014; 13: 133
2) Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell, 2013; 153: 747-758
3) Chen J, Chen S, Huang P, Meng XL, Clayton S, Shen JS, Grayburn PA. In vivo targeted delivery of ANGPTL8 gene for beta cell regeneration in rats. Diabetologia, 2015; 58: 1036-1044
4) Gusarova V, Alexa CA, Na E, Stevis PE, Xin Y, Bonner-Weir S, Cohen JC, Hobbs HH, Murphy AJ, Yancopoulos GD, Gromada J. ANGPTL8/betatrophin does not control pancreatic beta cell expansion. Cell, 2014; 159: 691-696
5) Fu Z, Berhane F, Fite A, Seyoum B, Abou-Samra AB, Zhang R. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci Rep, 2014; 4: 5013
6) Hu H, Sun W, Yu S, Hong X, Qian W, Tang B, Wang D, Yang L, Wang J, Mao C, Zhou L, Yuan G. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care, 2014; 37: 2718-2722
7) Gao T, Jin J, Chen P, Jin H, Yang L, Xie X, Yang M, Hu
C, Yu X. Circulating betatrophin correlates with triglycerides and postprandial glucose among different glucose tolerance statuses: a case-control study. PLoS One, 2015; 10: e0133640.

8) Yue S, Wu J, Zhang J, Liu L, Chen L. The relationship between betatrophin levels in blood and T2DM: a systematic review and meta-analysis. Dis Markers, 2016; 2016: 9391837

9) Gómez-Ambrosi J, Pascual E, Catalán V, Rodríguez A, Ramírez B, Silva C, Gil MJ, Salvador J, Frühbeck G. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab, 2014; 99: E2004-2009

10) Fenzl A, Itariu BK, Kosi L, Fritzer-Szekeres M, Kautzky-Willer A, Stulnig TM, Kiefer FW. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia, 2014; 57: 1204-1208

11) Guo K, Lu J, Yu H, Zhao F, Pan P, Zhang L, Chen H, Bao Y, Jia W. Serum betatrophin concentrations are significantly increased in overweight but not in obese or type 2 diabetic individuals. Obesity, 2015; 23: 793-797

12) Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun, 2012; 424: 786-792

13) Wang Y, Quagliarini F, Gusarova V, Valenzuela DM, Cohen HH. Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci USA, 2013; 110: 16109-16114

14) Maurer L, Schwarz F, Fischer-Rosinsky A, Schluerer N, Brachs S, Möhlig M, Pfeiffer A, Mai K, Spranger J, Bøtter T. Renal function is independently associated with circulating betatrophin. PLoS One, 2017; 12: e0173197

15) Huang Y, Fang C, Guo H, Hu J. Increased angiopoietin-like protein 8 levels in patients with type 2 diabetes and cardiovascular disease. Diabetes Res Clin Pract, 2016; 120: 229-231

16) Lee JY, Lee SW, Lee WS, Han S, Park YK, Kwon CH, Jang JY, Cho YR, Park GM, Ahn JM, Kim WJ, Park DW, Kang SJ, Kim YH, Lee CW, Park SW, Park SJ. Prevalence and clinical implications of newly revealed, asymptomatic abnormal ankle-brachial index in patients with significant coronary artery disease. JACC Cardiovasc Interv, 2013; 6: 1303-1313

17) Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol, 1996; 49: 1373-1379

18) Farber A, Eberhardt RT. The current state of critical limb ischemia: a systematic review. JAMA Surg, 2016; 151: 1070-1077

19) Nakamura E, Sato Y, Iwakiri T, Yamashita A, Moriguchi-Goto S, Maekawa K, Gi T, Asada Y. Asymptomatic plaques of lower peripheral arteries and their association with cardiovascular disease: an autopsy study. J Atheroscler Thromb, 2017; 2: 921-927

20) Mattijssen F, Kersten S. Regulation of triglyceride metabolism by angiopoietin-like proteins. Biochim Biophys Acta, 2012; 1821: 782-789

21) Georgiadi A, Wang Y, Stienstra R, Tjeerdeda N, Janssen A, Stalenhof A, van der Vliet JA, de Roos A, Tamsma JT, Smit JWA, Tan NS, Müller M, Rensen PCN, Kersten S. Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development. Arterioscler Thromb Vasc Biol, 2013; 33: 1529-1537

22) Smart-Halajko MC, Robciuc MR, Cooper JA, Jauhiainen M, Kumari M, Kivimaki M, Khaw KT, Boekholdt SM, Wareham NJ, Gaunt TR, Day IN, Braund PS, Nelson CP, Hall AS, Samani NJ, Humphries SE, Ehnholm C, Talmud PJ. The relationship between plasma angiopoitin-like protein 4 levels, angiopoietin-like protein 4 genotype, and coronary heart disease risk. Arterioscler Thromb Vasc Biol, 2010; 30: 2277-2282

23) Ando Y, Shimizuwa T, Takeshita S, Ono M, Shimamura M, Koishi R, Furukawa H. Decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice. J Lipid Res, 2003; 44: 1216-1223

24) Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, Natarajan P, Klarin D, Emdin CA, Zekavat SM, Nomura A, Atdemann J, Schunkert H, Samani NJ, Kraus WE, Shah SH, Yu B, Boerwinkle E, Rader DJ, Gupta N, Frossard PM, Rasheed A, Danesh J, Lander ES, Gabriel S, Saleheen D, Musunuru K, Kathiresan S. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol, 2017; 69: 2054-2063

25) Hatsuwa S, Shoji T, Shinohara K, Kimoto E, Mori K, Fukushima S, Koyama H, Emoto M, Nishizawa Y. Association between plasma angiopoietin-like protein 3 and arterial wall thickness in healthy subjects. J Vasc Res, 2007; 44: 61-66

26) Su X, Peng D. New insights into ANGPTL3 in controlling lipoprotein metabolism and risk of cardiovascular diseases. Lipids in Health and Disease, 2018; 17: 12

27) Haller JF, Mintah IJ, Shihanian LM, Stevis P, Buckler D, Alexa-Braun CA, Kleiner S, Banfi S, Cohen JC, Hobbs HH, Yancopoulos GD, Murphy AJ, Gusarova V, Gromada J. ANGPTL8 requires ANGPTL3 to inhibit lipoprotein metabolism and plasma triglyceride clearance. J Lipid Res, 2017; 58: E2004-2009

28) Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, Valenzuelag DM, Murphy AJ, Cohen JC, Hobbs HH. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA, 2012; 109: 19751-19756

29) Chi X, Britt EC, Shows HW, Hjelmaas AJ, Shetty SK, Cushing EM, Li W, Dou A, Zhang R, Davies BSJ. ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase. Mol Metab, 2017; 6: 1137-1149

30) Fu Z, Abou-Samra AB, Zhang R. An explanation for recent discrepancies in levels of human circulating betatrophin. Diabetologia, 2014; 57: 2232-2234